Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,100 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: STOP Therapy Treatment group Clear all
Recruiting Phase 1Phase 2 Interventional

A Bundled Intervention

NCT06593093
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Overdose
Interventions
a bundled intervention, control group
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00621686
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
bevacizumab, sorafenib tosylate
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
204
States / cities
Scottsdale, Arizona • Fresno, California • Fort Collins, Colorado + 129 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Not applicable Interventional Results available

Pharmacist Intervention to Improve Smoking Cessation

NCT06943287
View directory record Official record
Conditions
Smoking Cessation
Interventions
Pharmacist Intervention
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Completed No phase listed Observational

Meriter Mindfulness Training for Smokers Program and Study

NCT02143752
View directory record Official record
Conditions
Smoking
Interventions
Mindfulness, Quit Line
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

NCT01747915
View directory record Official record
Conditions
Generalized Tonic Clonic Seizures
Interventions
Pregabalin Dose Level 1, Pregabalin Dose Level 2, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
5 Years to 65 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
12
States / cities
Loxahatchee Groves, Florida • Orlando, Florida • Port Charlotte, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Sep 30, 2026, 5:13 AM EDT
Completed No phase listed Observational

A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients

NCT00407160
View directory record Official record
Conditions
Kidney Diseases
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Results available

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

NCT00866879
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Sep 30, 2026, 5:13 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

NCT05757869
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Milvexian, Apixaban, Placebo, Apixaban Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
20,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
216
States / cities
Alexander City, Alabama • Birmingham, Alabama • Dothan, Alabama + 182 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Ask Advise Connect (AAC) Harris Heath CPRIT

NCT01788787
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Quitline-Delivered Proactive Telephone Counseling, Follow-Up Phone Call, Smoking Cessation Training, Qualitative Interviews Concerning the Implementation of AAC
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5,212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2049
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tying Devices as a Means of Increasing Exercise

NCT01410812
View directory record Official record
Conditions
Healthy
Interventions
Control, Suggested Tying Intervention, Forced Tying Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Sep 30, 2026, 5:13 AM EDT
Withdrawn Phase 2 Interventional

iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)

NCT03207334
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Midostaurin, Cytarabine
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 4 Interventional

Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation

NCT00087581
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Mycophenolate mofetil, Cyclosporine, Tacrolimus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
57
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 48 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Sep 30, 2026, 5:13 AM EDT
Terminated Not applicable Interventional Results available

Improving Erectile Function and Quality of Life After Prostate Cancer Treatment

NCT01996852
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction Following Simple Prostatectomy, Erectile Dysfunction
Interventions
Cognitive-behavioral Meetings, sildenafil citrate, Vacuum Constriction Device
Behavioral · Drug · Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Sep 30, 2026, 5:13 AM EDT
Terminated Phase 3 Interventional Results available

Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients

NCT00311311
View directory record Official record
Conditions
Atherosclerosis, Kidney Failure
Interventions
tacrolimus, mycophenolate mofetil, prednisone, sirolimus
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

NCT03639311
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA, RPV LA, RPV, DTG
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating a Telephone-Based Smoking Cessation Program Among People in the Military (The AFIII Study)

NCT00632411
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Nicotine Patch, Tobacco Quit Line Program
Drug · Behavioral
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
1,298 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
2
States / cities
Memphis, Tennessee • Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

NCT02120352
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets, RPV Oral Tablets, HAART, RPV
Drug · Other
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Not applicable Interventional

Motivational Interviewing Compared to Psychoeducation for Smoking Precontemplators With SMI

NCT01982617
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Motivational Interviewing, Psychoeducation
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Results available

Baseline Oral Health Study: UnCoVer the Connections to General Health

NCT04954313
View directory record Official record
Conditions
Cardiovascular Diseases, Diabetes Type 2
Interventions
Subgingival chlorhexidine irrigation, Dental Supplies, Periodonal Treatment
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia

NCT01862250
View directory record Official record
Conditions
Encephalopathy, Hypoxic-Ischemic
Interventions
Clonidine (Duraclon®)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
35 Weeks to 42 Weeks
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Sep 30, 2026, 5:13 AM EDT
Terminated Phase 2Phase 3 Interventional

Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated

NCT06613685
View directory record Official record
Conditions
HIV-1-infection
Interventions
lepetegravir, lenacapavir pacfosacil, Bictegravir/emtricitabine/tenofovir alafenamide, lepetegravir/lenacapavir pacfosacil FDC, Placebo to Match BVY, Placebo to Match GS1720/GS-4182 FDC
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Torrance, California • West Hollywood, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Not applicable Interventional Results available

Combined CBIT and rTMS to Improve Tourette's Syndrome

NCT04795908
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Transcranial Magnetic Stimulation, Comprehensive behavioral intervention
Device · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 30, 2026, 5:13 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Cranial Electric Stimulation to Modify Suicide Risk Factors in Psychiatric Inpatients.

NCT02846740
View directory record Official record
Conditions
Suicide, Depression, Anxiety, Insomnia, Agitation
Interventions
Alpha-Stim®., Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, The Pittsburgh Sleep Quality Index and agitated behavior Scale
Device · Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 1 Interventional

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

NCT03381183
View directory record Official record
Conditions
Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma
Interventions
Durvalumab, IRX-2 Regimen
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Sep 30, 2026, 5:13 AM EDT